New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
07:06 EDTDYAX, NVLSDyax and Novellus partner to commercialize Kalbitor in Latin America
Dyax (DYAX) and Novellus (NVLS) announced a strategic partnership for the development and commercialization of Kalbitor (ecallantide) for the treatment of hereditary angioedema and other angioedema indications in select regions in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico and Venezuela. Kalbitor is marketed in the U.S. for the treatment of acute attacks of HAE in patients 16 years of age and older. Dyax will receive an upfront payment and is eligible to receive future sales milestones. Dyax is also eligible to receive royalties on net product sales. Novellus is solely responsible for all costs associated with necessary development, regulatory activities, and the commercialization of Kalbitor in the covered territories.
News For DYAX;NVLS From The Last 14 Days
Check below for free stories on DYAX;NVLS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
08:02 EDTDYAXDyax names Todd Bazemore as Chief Commercial Officer
Dyax Corp. announced the appointment of Todd Bazemore as Executive Vice President and Chief Commercial Officer. Bazemore will be responsible for leading Dyax’s commercial organization which currently markets KALBITOR for the treatment of acute attacks of hereditary angioedema in patients 12 years of age and older. Bazemore most recently served as Vice President, Managed Markets at Sunovion Pharmaceuticals.
April 3, 2014
16:07 EDTDYAXDyax gets FDA approval for expanded use of Kalbitor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use